These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 18786981)
1. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Lee SM; James LE; Qian W; Spiro S; Eisen T; Gower NH; Ferry DR; Gilligan D; Harper PG; Prendiville J; Hocking M; Rudd RM Thorax; 2009 Jan; 64(1):75-80. PubMed ID: 18786981 [TBL] [Abstract][Full Text] [Related]
2. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L; Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation. Steele JP Semin Oncol; 2001 Jun; 28(3 Suppl 10):15-8. PubMed ID: 11510029 [TBL] [Abstract][Full Text] [Related]
4. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW; Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212 [TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097 [TBL] [Abstract][Full Text] [Related]
10. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey. Bayman E; Etiz D; Akcay M; Ak G Asian Pac J Cancer Prev; 2014; 15(15):6263-7. PubMed ID: 25124609 [TBL] [Abstract][Full Text] [Related]
11. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307 [TBL] [Abstract][Full Text] [Related]
12. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472 [TBL] [Abstract][Full Text] [Related]
13. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. de Castria TB; da Silva EM; Gois AF; Riera R Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060 [TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A; Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. Sederholm C; Hillerdal G; Lamberg K; Kölbeck K; Dufmats M; Westberg R; Gawande SR J Clin Oncol; 2005 Nov; 23(33):8380-8. PubMed ID: 16293868 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458 [TBL] [Abstract][Full Text] [Related]
19. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Yamamoto N; Nakagawa K; Uejima H; Sugiura T; Takada Y; Negoro S; Matsui K; Kashii T; Takada M; Nakanishi Y; Kato T; Fukuoka M; Cancer; 2006 Aug; 107(3):599-605. PubMed ID: 16804877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]